Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress
November 15 2013 - 9:33PM
Business Wire
The Burzynski Clinic (BC) announced today that it made a keynote
speaker presentation at the 2nd Annual Congress of Asia-Pacific
Academy of Anti-Aging Medicine in Beijing, China. Based on the
presentation in Beijing, a total of 401 eligible patients (patients
who received over 28 days of treatment) with advanced inoperable
brain tumors have been treated with antineoplaston A10 and
antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of
the patients (87%) were diagnosed with high-grade tumors and the
remaining patients were diagnosed with low-grade tumors. The
patients were diagnosed by pathologists not associated with BC and
objective responses were verified by Central Radiology Review. The
group of 77 patients (19%) survived over five years from the
treatment start. Of particular interest were results in patients
with brainstem gliomas. The group of 17 patients with brainstem
glioma underwent the treatment and 65% of these patients survived
over five years. An additional group of 42 patients diagnosed with
diffuse intrinsic pontine glioma (DIPG) have been treated and a
total of 19% survived over five years.
The quality of survival is very good and there is no long-term
toxicity related to ANP.
These clinical results are very encouraging, since they describe
a positive ANP effect on some of the worst malignancies in the
entire oncology field, but they will require FDA approval.
Burzynski Clinic is committed to developing treatments for
cancer based on genomic and epigenomic principles.
Forward-looking statements in this release are made pursuant to
the safe harbor provisions of the federal securities laws.
Information contained in forward-looking statements is based on
current expectations and is subject to change, and future events
may differ materially from those discussed herein due to a number
of factors, including, but not limited to, risks and uncertainties
related to the clinic’s ability to use Antineoplastons A10 and
AS2-1. Burzynski Clinic does not undertake to update any such
forward-looking statements or to publicly announce developments or
events relating to the matters described herein.
For Burzynski ClinicCarolyn Powers,
713-335-5664carolyn@burzynskiclinic.com
Burzynski Research Insti... (PK) (USOTC:BZYR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Burzynski Research Insti... (PK) (USOTC:BZYR)
Historical Stock Chart
From Sep 2023 to Sep 2024
